| P50 | author | Carolyn Doree | Q28036971 |
| | Simon Stanworth | Q28036972 |
| | Marialena Trivella | Q28037027 |
| | Michael J Desborough | Q45381883 |
| | Lise J Estcourt | Q56850962 |
| P2093 | author name string | Michael F Murphy | |
| | Sally Hopewell | |
| P2860 | cites work | Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders | Q24186028 |
| | Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review | Q24186703 |
| | Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation | Q24197779 |
| | A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation | Q24198288 |
| | Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation | Q24198774 |
| | Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation | Q24198795 |
| | Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation | Q24198832 |
| | Pathogen-reduced platelets for the prevention of bleeding | Q24199041 |
| | Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders | Q24201018 |
| | Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia | Q24201292 |
| | Pathogen-reduced platelets for the prevention of bleeding | Q24235318 |
| | TPO receptor agonist for chronic idiopathic thrombocytopenic purpura | Q24235481 |
| | Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation | Q24245960 |
| | Hematopoietic stem cell transplantation: a global perspective | Q24624697 |
| | Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 |
| | Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 |
| | The EBMT activity survey: 1990-2010 | Q28265604 |
| | Evaluation of platelet transfusion triggers in a tertiary-care hospital | Q28288397 |
| | Dose of prophylactic platelet transfusions and prevention of hemorrhage | Q30496886 |
| | A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation | Q33331726 |
| | A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia | Q33332022 |
| | Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia | Q33332601 |
| | Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer | Q33333351 |
| | Low-dose intranasal desmopressin (DDAVP) for uremic bleeding | Q73069174 |
| | Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group | Q73426858 |
| | Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ib alpha under flow conditions: specific synergy of receptor-ligand interactions | Q74314265 |
| | 45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California | Q75235177 |
| | Transfusion guidelines for neonates and older children | Q76382875 |
| | Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome | Q77537326 |
| | Agents to control bleeding show promise | Q79631980 |
| | Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation | Q81064697 |
| | Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis | Q84106542 |
| | [Clinical study on platelet engraftment by thrombopoietin in patients with hematological malignancies after allogeneic hematopoietic stem cell transplantation] | Q84560762 |
| | Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial | Q87457366 |
| | Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. | Q36694890 |
| | Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology | Q33336231 |
| | Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study | Q33336625 |
| | Novel platelet products, substitutes and alternatives | Q33338494 |
| | Thrombocytopenia caused by the development of antibodies to thrombopoietin | Q33339929 |
| | The impact of thrombopoietin on clinical practice | Q33342875 |
| | The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation | Q33344246 |
| | Guidelines for the use of platelet transfusions | Q33348675 |
| | Substitutes and alternatives to platelet transfusions in thrombocytopenic patients | Q33349074 |
| | Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and effic | Q33357084 |
| | Measurement of bleeding severity: a critical review | Q33360118 |
| | The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia | Q33360274 |
| | Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? | Q33361871 |
| | A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor | Q33362720 |
| | Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients | Q33364823 |
| | Platelet utilization and the transfusion trigger: a prospective analysis | Q33374264 |
| | Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. | Q33376695 |
| | Lack of efficacy of tranexamic acid in thrombocytopenic bleeding | Q33378472 |
| | Emerging treatments for thrombocytopenia: increasing platelet production | Q33380212 |
| | The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia | Q33381443 |
| | A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia | Q33382568 |
| | Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute | Q33382776 |
| | Evaluation of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in lung cancer patients | Q33382946 |
| | Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome | Q33385999 |
| | Novel platelet substitutes: disk-shaped biodegradable nanosheets and their enhanced effects on platelet aggregation | Q33386421 |
| | Effect of beta-blockers, Ca2+ antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia | Q33387124 |
| | Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia | Q33387521 |
| | Biology and chemistry of thrombopoietic agents | Q33390625 |
| | Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy | Q33390778 |
| | Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic plat | Q33390939 |
| | Effect of Hepatic or Renal Impairment on Eltrombopag Pharmacokinetics | Q33391009 |
| | A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. | Q33391571 |
| | Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial | Q33391829 |
| | Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes | Q33392293 |
| | A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when | Q33399717 |
| | The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review | Q36784987 |
| | Evidence-based platelet transfusion guidelines | Q37007307 |
| | Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials | Q37147203 |
| | Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review | Q37164735 |
| | Recombinant activated factor VII as a general haemostatic agent: evidence-based efficacy and safety | Q37239468 |
| | Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission | Q37369934 |
| | ABO-identical versus nonidentical platelet transfusion: a systematic review | Q37630711 |
| | The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding | Q37973517 |
| | Plasma transfusion for bedside, radiologically guided, and operating room invasive procedures | Q38009414 |
| | The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions | Q38073018 |
| | Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. | Q38451297 |
| | Platelet utilization in the developing world: strategies to optimize platelet transfusion practices | Q39951057 |
| | Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. | Q40429557 |
| | Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. | Q40494663 |
| | The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy | Q40725565 |
| | Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. | Q41608625 |
| | TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders | Q42085145 |
| | Pharmacokinetics and safety of fibrinogen concentrate | Q42635685 |
| | Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial | Q43077299 |
| | Screening of platelets for bacterial contamination at the Welsh Blood Service | Q43483591 |
| | Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study | Q43889424 |
| | Pharmacodynamic modeling of thrombopoietin, platelet, and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy | Q43997705 |
| | Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors | Q44189779 |
| | Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. | Q46009743 |
| | Platelet transfusions in haematology patients: are we using them appropriately? | Q47405698 |
| | Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery followin | Q47604054 |
| | Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. | Q51839300 |
| | Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. | Q53446336 |
| | Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels. | Q53569139 |
| | Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. | Q53770407 |
| | Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials | Q57076584 |
| | A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia | Q58414478 |
| | Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients | Q67670127 |
| | [Substitution with blood coagulation factor XIII concentrates in patients with acute leukemia] | Q68899953 |
| | Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia | Q69371276 |
| | DDAVP: does the drug have a direct effect on the vessel wall? | Q70453385 |
| | DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium | Q70483548 |
| | Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial | Q71299208 |
| | [Blood clotting factor XIII substitution in acute leukaemia: result of a randomized and controlled study] | Q71453317 |
| | The use of anti-D to improve post-transfusion platelet response: a randomized trial | Q72444983 |
| | [Effect of testosterone propionate and 1-methyl-1-androstenolone on blood coagulation factors, bromsulphalein retention and serum enzymes as parameters of liver function] | Q72822310 |
| | Prophylactic recombinant human thrombopoietin treatment alleviates chemotherapy- induced thrombocytopenia in tumor patients | Q33402485 |
| | Thrombopoietin-receptor agonists | Q33402729 |
| | Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study | Q33402744 |
| | A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine | Q33402882 |
| | A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide | Q33404600 |
| | Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review | Q33406794 |
| | A no-prophylaxis platelet-transfusion strategy for hematologic cancers | Q33407550 |
| | Recombinant human thrombopoietin is an effective treatment for thrombocytopenia in hemophagocytic lymphohistiocytosis | Q33408467 |
| | Does bleeding affect patient-reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review | Q33410860 |
| | A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation | Q33410880 |
| | Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study | Q33412573 |
| | Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia | Q33414453 |
| | A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine | Q33415466 |
| | Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes | Q33416541 |
| | Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials | Q33417304 |
| | Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study | Q33417372 |
| | Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia | Q33424820 |
| | Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial | Q33428549 |
| | Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. | Q33452988 |
| | The Prophylactic Treatment of Thrombocytopenic Leukemic Patients with Platelets: a Double Blind Study | Q33465206 |
| | Trial of a new hemostatic: dicynone | Q33467274 |
| | Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer | Q33497646 |
| | Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer | Q33499132 |
| | Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies | Q33501160 |
| | Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions | Q33501221 |
| | Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation | Q33756657 |
| | Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery | Q33793633 |
| | The platelet as an immune cell-CD40 ligand and transfusion immunomodulation | Q33937074 |
| | Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. | Q35131637 |
| | Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. | Q35940036 |
| | Eltrombopag and improved hematopoiesis in refractory aplastic anemia | Q36174878 |
| | Platelet mimetic particles for targeting thrombi in flowing blood | Q36355586 |
| | Exogenous endothelial cells as accelerators of hematopoietic reconstitution | Q36527110 |
| P433 | issue | 8 | |
| P921 | main subject | chemotherapy | Q974135 |
| | platelet transfusion | Q23925170 |
| P304 | page(s) | CD010982 | |
| P577 | publication date | 2016-08-22 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation | |